Screening of MicroRNA in Patients with Esophageal Cancer at Same Tumor Node Metastasis Stage with Different Prognoses

  • Zhao, Bao-Sheng (Department of Thoracic Surgery, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Liu, Shang-Guo (Department of Thoracic Surgery, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Wang, Tian-Yun (Department of Biochemistry and Molecular Biology, Xinxiang Medical University) ;
  • Ji, Ying-Hua (Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Qi, Bo (Department of Thoracic Surgery, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Tao, Yi-Peng (Department of Thoracic Surgery, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Li, Han-Chen (Department of Thoracic Surgery, the First Affiliated Hospital of Xinxiang Medical University) ;
  • Wu, Xiang-Nan (Department of Biochemistry and Molecular Biology, Xinxiang Medical University)
  • Published : 2013.01.31


Patients at the same pathological stage of esophageal cancer (EC) that received the same surgical therapy by the same surgeon may have distinct prognoses. The current study aimed to explore the possibility of differentially-expressed microRNAs (miRNAs) underlying this phenomenon. Samples were collected from EC patients at the same tumor node metastasis (TNM) stage but with different prognoses. Paracancerous normal tissues were taken as controls. The specimens were histopathologically analyzed. Differentially-expressed miRNAs were analyzed using real-time quantitative reverse transcription polymerase chain reaction. Compared with patients with poor prognosis, those with good prognosis exhibited 88 two-fold or more than two-fold increased miRNA fragments and 4 half-decreased miRNAs. The most noticeably up-regulated miRNAs included hsa-miR-31, hsa-miR-196b, hsa-miR-652, hsa-miR-125a-5p, hsa-miR-146b, hsa-miR-200c, hsa-miR-23b, hsa-miR-29a, hsa-miR-186, hsa-miR-205, hsa-miR-376a, hsa-miR-410, hsa-miR-532-3p, and hsa-miR-598, whereas the most significantly-downregulated miRNAs were hsa-let-7e, hsa-miR-130b, and hsa-miR-103. EC patients at same TNM stage but with different prognoses show differentially-expressed miRNAs.


  1. Nakashima H, Naqahama R, Yoshida M (2012). Present and future state of cancer screening for esophageal cancer and gastric cancer. Gao To Kagaku Ryoho, 39, 8-12.
  2. Nitsche U, Rosenberg R, Balmert A, et al (2012). Integrative Marker Analysis Allows Risk Assessment for Metastasis in Stage II Colon Cancer. Ann Surg, 256, 763-71.
  3. Ogawa R, Ishiguro H, Kuwabara Y, et al (2009). Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol, 42, 102-9.
  4. Ohta M, Mimofi K, Fukuyoshi Y, et al (2008). Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer, 98, 410-7.
  5. Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL (2007). The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer, 97, 1404-8.
  6. Talsma K, van Hagen P, Grotenhuis BA, et al (2012). Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol, 19, 2142-8.
  7. Usami S, Motoyama S, Matsuhashi T, et al (2012). Outcomes of endoscopic and surgical resection for a second primary cancer in the residual cervical esophagus after thoracic esophagectomy. Dis Esophagus, 25, 228-34.
  8. Wang SY, Mao WM, Du XH, Xu YP, Zhang SZ (2012). The 2002 AJCC TNM classification is a better predictor of esophageal primary small cell carcinoma outcome than the VALSG staging system. Chin J Cancer. Oct 10. doi:10.5732/cjc.012.10161
  9. Xu X, Chen Z, Zhao X, et al (2012). MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 421, 640-5.
  10. Yang M, Liu R, Sheng J, et al (2013). Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep, 29, 169-76.
  11. Zhang C, Wang C, Chen X, et al (2010). Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem, 56, 1871-9.
  12. Zhang JX, Tong ZT, Yang L, et al (2012). PITX2: A promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer.
  13. Zhou ZQ, Cao WH, Xie JJ, et al (2009). Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer, 9, 291.
  14. Zhu X, Ding M, Yu ML, et al (2010). Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer, 10, 290.
  15. Zhu ZJ, Hu Y, Zhao YF, et al (2011). Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg, 91, 1502-8.
  16. Feber A, Xi L, Luketich JD, et al (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-60.
  17. Griffin SM, Burt AD, Jennings NA (2011). Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg, 254, 731-6.
  18. Guo Y, Chen Z, Zhang L, et al (2008). Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res, 68, 26-33.
  19. He B, Pan Y, Cho WC, et al (2012). The Association between Four Genetic Variants in MicroRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and Cancer Risk: Evidence from Published Studies. PLoS One, 7, e49032.
  20. Kim SM, Park YY, Park ES, et al (2010). Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One, 5, e15074.
  21. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN (2005). The molecular biology of esophageal adenocarcinoma. J Surg Oncol, 92, 169-90.
  22. Lin RJ, Xiao DW, Liao LD, et al (2012). MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol, 105, 175-82.
  23. Lumen N, Fonteyne V, De Meerleer G, et al (2012). Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg, 67, 270-5.
  24. Mao WM, Zheng WH, Ling ZQ (2011). Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev, 12, 2461-6.
  25. Mathe EA, Nguyen GH, Bowman ED, et al (2009). MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res, 15, 6192-200.

Cited by

  1. MIR376A Is a Regulator of Starvation-Induced Autophagy vol.8, pp.12, 2013,
  2. Optimization of Reference Genes for Normalization of the Quantitative Polymerase Chain Reaction in Tissue Samples of Gastric Cancer vol.15, pp.14, 2014,
  3. HOXB7 Predicts Poor Clinical Outcome in Patients with Advanced Esophageal Squamous Cell Cancer vol.15, pp.4, 2014,
  4. Exosome-derived microRNA-29c Induces Apoptosis of BIU-87 Cells by Down Regulating BCL-2 and MCL-1 vol.15, pp.8, 2014,
  5. Diagnostic and Prognostic Value of miR-205 in Colorectal Cancer vol.15, pp.9, 2014,
  6. miR-186, miR-3651 and miR-494: Potential biomarkers for oral squamous cell carcinoma extracted from whole blood vol.31, pp.3, 2014,
  7. The miRNA23b-regulated signaling network as a key to cancer development—implications for translational research and therapeutics vol.92, pp.11, 2014,
  8. A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy vol.10, pp.3, 2015,
  9. Identification of miR-130b as an oncogene in renal cell carcinoma vol.13, pp.2, 2015,
  10. MicroRNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis vol.21, pp.11, 2015,
  11. MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1 vol.36, pp.1, 2015,
  12. Expression of the circulating and the tissue microRNAs after surgery, chemotherapy, and radiotherapy in mice mammary tumor vol.37, pp.10, 2016,
  13. MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus vol.37, pp.6, 2016,
  14. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair vol.10, pp.1, 2017,
  15. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients vol.113, pp.1, 2015,
  16. Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors vol.14, pp.16, 2015,
  17. Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients vol.12, pp.1, 2016,
  18. Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative Colitis vol.24, pp.1, 2017,
  19. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling pp.1476-5594, 2018,
  20. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells vol.18, pp.1, 2018,
  21. MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells vol.15, pp.1, 2015,